Engineered adar-recruiting rnas and methods of use thereof

Patent metadata

Field	Value
Publication number	US-2025001011-A1
Application number	US-202218684082-A
Country	US
Kind code	A1
Filing date	Aug 18, 2022
Priority date	Aug 18, 2021
Publication date	Jan 2, 2025
Grant date	—

Abstract

Provided are methods for editing RNA by introducing a deaminase-recruiting RNA in a host cell for deamination of an adenosine in a target RNA, methods for reducing off-target editing of RNA, deaminase-recruiting RNAs used in the RNA editing methods and compositions and kits comprising the same.

First claim

1 : A method for editing a target adenosine in a target RNA in a host cell, comprising introducing a deaminase-recruiting RNA (dRNA) or a construct comprising a nucleic acid sequence encoding the dRNA into the host cell, wherein:
(1) the dRNA comprises a targeting RNA sequence that is capable of hybridizing to the target RNA to form a duplex RNA, wherein the duplex RNA comprises a bulge comprising a non-target adenosine in the target RNA; and (2) the dRNA is capable of recruiting an adenosine deaminase acting on RNA (ADAR).

2 : The method of claim 1 , wherein the duplex RNA comprises a bulge at each non-target adenosine in the target RNA.

3 : The method of claim 1 , wherein the targeting RNA sequence is complementary to the target RNA except for lacking one or more nucleotides opposite to non-target adenosines in the target RNA.

4 . (canceled)

5 : The method of claim 1 , wherein the method has reduced level of editing of the non-target adenosine in the target RNA compared to a method using a dRNA or a construct thereof comprising a targeting RNA sequence that has a nucleotide opposite the non-target adenosine in the target RNA.

6 : The method of claim 1 , wherein the dRNA is a linear RNA.

7 : The method of claim 6 , wherein the dRNA is capable of forming a circular RNA.

8 : The method of claim 1 , wherein the dRNA is a circular RNA.

9 : The method of claim 1 , wherein the dRNA comprises a linker nucleic acid sequence flanking an end of the targeting RNA sequence, wherein the linker nucleic acid sequence does not substantially form any secondary structure with any part of the dRNA.

10 : The method of claim 1 , wherein the dRNA comprises a linker nucleic acid sequence replacing an end of the targeting RNA sequence, wherein the linker nucleic acid sequence does not substantially form any secondary structure with any part of the dRNA.

11 : A method for editing a target adenosine in a target RNA in a host cell, comprising introducing a dRNA or a construct comprising a nucleic acid sequence encoding the dRNA into the host cell, wherein:
(1) the dRNA comprises a targeting RNA sequence that is capable of hybridizing to the target RNA, wherein the dRNA comprises a linker nucleic acid sequence flanking an end of the targeting RNA sequence, wherein the linker nucleic acid sequence does not substantially form any secondary structure with any part of the dRNA; (2) the dRNA is capable of recruiting an ADAR; and (3) the dRNA is a circular RNA or a linear RNA capable of forming a circular RNA.

12 : The method of claim 11 , wherein the dRNA is a circular RNA.

13 : The method of claim 11 , wherein the dRNA is a linear RNA capable of forming a circular RNA.

14 : The method of claim 11 , wherein the linker nucleic acid sequence is about 5 nucleotides (nt) to about 500 nt long.

15 : The method of claim 14 , wherein the linker nucleic acid sequence is about 50 nt to about 500 nt long.

16 - 17 . (canceled)

18 : The method of claim 11 , wherein at least about 50% of the linker nucleic acid sequence comprises adenosine or cytidine; optionally wherein 100% of the linker nucleic acid sequence comprises adenosine or cytidine.

19 - 28 . (canceled)

29 : The method of claim 11 , wherein the dRNA is a circular RNA, and wherein the linker nucleic acid sequence connects the 5′ end of the targeting RNA sequence and the 3′ end of the targeting RNA sequence.

30 - 62 . (canceled)

63 : A method for treating or preventing a disease or condition in an individual, comprising editing a target RNA associated with the disease or condition in a cell of the individual according to the method of claim 1 .

64 - 68 . (canceled)

69 : A dRNA for editing a target RNA comprising a targeting RNA sequence that is capable of hybridizing to the target RNA, wherein the dRNA comprises a linker nucleic acid sequence flanking an end of the targeting RNA sequence, wherein the linker nucleic acid sequence does not substantially form any secondary structure with any part of the dRNA, and wherein the dRNA is a circular RNA or a linear RNA capable of forming a circular RNA.

70 - 73 . (canceled)

74 : A method for treating or preventing a disease or condition in an individual, comprising editing a target RNA associated with the disease or condition in a cell of the individual according to the method of claim 11 .

Assignees

• Univ Beijing
• Edigene Therapeutics Beijing Inc

Inventors

• Wei Wensheng
• Yi Zongyi
• Yuan Pengfei

Classifications

• C12Y305/04

  in cyclic amidines (3.5.4) · CPC title

• C12N2750/14143

  viral genome or elements thereof as genetic vector · CPC title

• C12N15/90

  Stable introduction of foreign DNA into chromosome · CPC title

• C12N15/86

  Viral vectors · CPC title

• C12N15/11

  DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity} · CPC title